> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Medical Imaging Panel to Review Alzheimer’s Diagnostic
- URL: https://www.fdaweb.com/medical-imaging-panel-to-review-alzheimers-diagnostic/
- Published: 2020-02-19T12:00:00.000Z
- Updated: 2026-09-14T16:03:43.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5146121

*Federal Register* notice: FDA has announced a 4/23 Medical Imaging Drugs Advisory Committee meeting. Panel members are set to discuss an Avid Radiopharmaceuticals NDA for of flortaucipir F18 intravenous injection, a radioactive diagnostic agent for positron emission tomography brain imaging to estimate the density and distribution of aggregated tau neurofibrillary tangles in Alzheimer’s patients. Avid is an Eli Lilly subsidiary. To view the notice, click [here](https://s3.amazonaws.com/public-inspection.federalregister.gov/2020-03424.pdf?ref=fdaweb.com).